
|Videos|June 4, 2019
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
Author(s)Keith T. Flaherty, MD
Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5





























